Status and phase
Conditions
Treatments
About
Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers.
In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.
Full description
All patients will have the tumour cells diagnosed with a large genepanel, analyzing more than 500 genes on DNA / RNA level. Patients will be treated based on the molecular characteristics of the tumor cells.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
96 participants in 1 patient group
Loading...
Central trial contact
Kathinka Slørdahl, MD PhD; Åslaug Helland, MD PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal